I am pleased to announce that our lab has been awarded a new grant from the Congressionally Directed Medical Research Programs (CDMRP) – Peer Reviewed Cancer Research Program (PRCRP).
Running from 2025 to 2027, this project (Award No. HT94252510332) is titled “Multispecific Bridge Nanoparticles to Engage T Cells and Off-the-Shelf CAR-T Cells Against Antigen(+) EC Tumors to Enhance Antitumor Immune Activity.”
This funding will support our research into “bridge nanoparticles”—a novel platform designed to physically link T cells and off-the-shelf CAR-T cells directly to tumors. By creating a stronger engagement between the immune system and the cancer cells, we aim to significantly enhance antitumor immune activity and improve outcomes for patients with antigen-positive EC tumors.
We are grateful for the support from the CDMRP and look forward to advancing this promising technology over the next two years. All glory be to Jesus for this timely award.
Recent Comments